Since multidrug therapeutic regimens have shown a reduced risk of non-specific adverse effects, the strong efficacy of NRP1/Gal-1 combined targeting offers a promising perspective for regaining therapeutic efficacy for BRAF inhibitors in melanomas that have developed drug-resistance. Here, LGALS1 is linked to melanoma.